UPDATE : Friday, July 10, 2020
Bridge Biotherapeutics passes preliminary review for Kosdaq listing by Jeong Sae-im 2019-10-25 15:05
KangStem Biotech fails in phase-3 study on atopic dermatitis drug by Jeong Sae-im 2019-10-25 11:17
Value assessment on anticancer drugs hotly discussed by Jeong Sae-im 2019-10-24 13:46
PharmAbcine sets up US unit to develop anticancer drug by Jeong Sae-im 2019-10-23 15:48
‘Oral drugs as effective as inhalers for elderly with asthma’ by Jeong Sae-im 2019-10-22 15:48
Dong-A ST leaves KPBMA to ‘repent of illegal rebate’ by Jeong Sae-im 2019-10-21 16:42
Drug firms’ Q3 earnings to be fairly good by Jeong Sae-im 2019-10-21 12:27
Medytox exported ₩3.3 billion worth of unqualified BTX by Jeong Sae-im 2019-10-18 16:02
US sales of Remicade drop due to biosimilar’s rise by Jeong Sae-im 2019-10-17 13:32
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar by Jeong Sae-im 2019-10-16 14:16
Kolon Life Science shares surge after TissueGene’s survival by Jeong Sae-im 2019-10-14 18:01
HLB merges with Elevar to own rivoceranib rights by Jeong Sae-im 2019-10-14 14:43
‘Kosdaq firms listed for exceptional tech need special monitoring’ by Jeong Sae-im 2019-10-07 15:51
Samsung execs pass buck to biotech subsidiaries for destroying evidence by Jeong Sae-im 2019-10-04 11:42
Regulator raids cell therapy makers too often to little avail by Jeong Sae-im 2019-10-02 11:23
Will parliamentary audit uncover why Invossa was mislabeled? by Jeong Sae-im 2019-10-01 15:45
Ranitidine recall taking heavy toll on pharmaceuticals by Jeong Sae-im 2019-09-30 15:16
Regulator explained why it banned stomach medicine ranitidine altogether by Jeong Sae-im 2019-09-27 15:02
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’ by Jeong Sae-im 2019-09-26 15:24
Helixmith blames hospital for absurd drug mix-up by Jeong Sae-im 2019-09-25 13:42
Back to Top